Real-World Use of Alirocumab: Experience from a Large Healthcare Provider

Avishay Elis, Cheli Melzer Cohen*, Gabriel Chodick

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


With the emerging use of anti-PCSK9 monoclonal antibodies for lowering low-density lipoprotein cholesterol (LDL-C) levels, real-world evidence (RWE) is needed to evaluate drug effectiveness. This study aimed to characterize new users of alirocumab and evaluate its effectiveness in achieving LDL-C target levels. Included were patients initiating treatment with alirocumab from 1 August 2016 to 1 May 2020, with blood lipids evaluations during baseline (180 days prior to therapy initiation) and after 120 (±60) days of follow-up. Patients with treatment intensification during the follow-up period were excluded. LDL-C change from baseline and reaching LDL-C target levels, according to 2019 ESC/EAS guidelines, were evaluated. Among 623 included patients, 50.2% were men, the mean age was 65 years (±9 y), 62% were classified as very-high risk, and 76% had statin intolerance. During the follow-up, 65% (n = 407) were treated only with alirocumab. In 90% the initiation dose was 75 mg, and 21% were up-titrated. Alirocumab was associated with a 31.7% reduction in LDL-C, with 20.5% of patients reaching target levels. In this RWE study, alirocumab was used primarily as a single agent for eligible patients. Suboptimal use and adherence to therapy may have led to a lower LDL-C reduction compared to previous RCTs and most reported real-world studies.

Original languageEnglish
Article number1084
JournalJournal of Clinical Medicine
Issue number3
StatePublished - Feb 2023


FundersFunder number


    • LDL-C
    • alirocumab
    • anti-PCSK9 monoclonal antibodies
    • real-world evidence
    • target levels


    Dive into the research topics of 'Real-World Use of Alirocumab: Experience from a Large Healthcare Provider'. Together they form a unique fingerprint.

    Cite this